CURRICULUM VITAE
Tyce J. Kearl PhD, MD
Tyce J. Kearl PhD, MD
Assistant Professor
Department of Medicine
Division of Medicine Hematology Oncology
Department of Medicine
Division of Medicine Hematology Oncology
OFFICE ADDRESS: |
9200 West Wisconsin Avenue |
Milwaukee, WI 53226 |
FACULTY APPOINTMENTS: |
07/01/2022 - Present Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
06/2014 - 06/2017 American Academy of Pediatrics |
07/2017 - Present American Society of Hematology |
07/2017 - Present American Society of Pediatric Hematology and Oncology |
08/2020 - Present Society for the Immunotherapy of Cancer |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
International |
Kearl T and Zenga J, Improving T Cell Tumor-Specificity Using Single Cell Co-culture, The Scientist, live webinar, 381 registrants, 63% international, 10/02/2024 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
10/01/2022 - Present member, Institutional Biosafety Committee, Medical College of Wisconsin |
05/01/2024 - Present Vice Chair, Institutional Biosafety Committee, Medical College of Wisconsin |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Dice MS, Kearl T, Ruben PC. Methods for studying voltage-gated sodium channels in heterologous expression systems. Methods Mol Med. 2006;129:163-85. |
2. Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M. Phosphatidylethanolamine is externalized at the surface of microparticles. Biochim Biophys Acta. 2012 Dec;1821(12):1501-7. PMCID: PMC3809829 |
3. Kearl TJ, Jing W, Gershan JA, Johnson BD. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. J Immunol. 2013 Jun 01;190(11):5620-8. PMCID: PMC3891840 |
4. Thakar MS, Kearl TJ, Malarkannan S. Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Front Oncol. 2019;9:1529. PMCID: PMC7006459 |
5. Zenga J, Awan M, Frei A, Foeckler J, Kuehn R, Espinosa OV, Bruening J, Massey B, Wong S, Shreenivas A, Shukla M, Kasprzak J, Sun Y, Shaheduzzaman M, Chen F, Kearl T, Himburg HA. Tumor-specific T cells in head and neck cancer have rescuable functionality and can be identified through single-cell co-culture. Transl Oncol. 2024;42:101899. Corrigendum in Transl Oncol. 2024;44:101927. PMCID: PMC10851216. |
6. Zenga J, Himburg HA, Wong SJ, Kearl T, Hematti P, Jin VX, Memon AA, Mathison AJ, Awan MJ. In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations. Oral Oncology. September 2024;156. |
7. Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. Cancer Metastasis Rev. 2024 Dec 01;44(1):12. |
8. Zenga J, Awan MJ, Frei A, Foeckler J, Kuehn R, Kasprzak J, Massey B, Bruening J, Akakpo K, Shukla M, Wong SJ, Mathison AJ, Wendt Andrae J, Hunt B, Puzyrenko A, Jin VX, Memon AA, Villarreal Espinosa O, Chen F, Shaheduzzaman M, Kearl T, Hematti P, Himburg HA. Radiation therapy results in preferential tumor antigen-specific lymphodepletion in head and neck cancer. Nat Commun. 2025 Jul 01;16(1):5660. PMCID: PMC12219838 |
9. Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2285-2295. |
10. Quamine AE, Dray EL, Mohrdieck NR, King CA, Griggs AA, Kline JM, Cho MM, Rinella SP, Tippins KE, Bates PD, Shi L, Song L, Hess NJ, Kearl TJ, Johnson BD, Capitini CM. TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant. J Immunother Cancer. 2025 Dec 12;13(12). PMCID: PMC12699621 |
11. Said I, Awan MJ, Wong SJ, Memon AA, Kearl T, Hematti P, Massey B, Bruening J, Akakpo K, Zenga J, Himburg HA. Radiation-Induced Loss of Tumor-Reactive T Cells Calls for More Rationally Designed Radioimmunotherapy Approaches. Int J Radiat Oncol Biol Phys. 2026 Jan 01;124(1):190-193. PMCID: PMC12939519 |
12. Pham DL, Kalluri M, Weaver C, Hsu A, Gillette A, Zhao W, et al. Autofluorescence imaging reveals the impact of cryopreservation on T cell metabolism and activation response. Mol Ther Adv. 2026 July 34(2). |
13. Parashar D, Palen K, Sharma A, Pandey S, Kearl T, Hu P, et al. Clinical-Grade Armored BCMA CAR-T Cells Overcome TGF-β–Mediated Immunosuppression in Multiple Myeloma. Blood Immunol Cell Ther. 2026, in press. |
14. Memon AA, Said I, Norenberg E, Frei A, Foeckler J, Sun F, Dwinell MB, Lochhead RB, Bruening J, Akakpo K, Massey B, Wong SJ, Hematti P, Kearl TJ, Awan MJ, Himburg HA, Zenga J. Radiation-induced remodeling of the T cell landscape in head and neck cancer. Cancer Immunol Immunother. 2026 Apr 15;75(5). PMCID: PMC13083680 |
15. Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR. Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28;10(8):2698-2710. PMCID: PMC13101680 |
16. Shah V, Womack JA, Palen K, Johnson BD, Hematti P, Kearl TJ, Shah NN, Terhune SS, Dash RK. Data-driven computational modeling of CAR-T cell function. Front Immunol. 2026;17:1707783. PMCID: PMC13212496 |
